OrbiMed Advisors NKTX Position
Exited10-Fund ConvergenceOrbiMed Advisors exited their position in Nkarta, Inc. (NKTX) in Q2 2025, after holding the stock for 6 quarters.
The position was first reported in Q1 2024 and has been tracked across 6 quarterly 13F filings.
NKTX is a convergence signal: 10 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for NKX019 in 379 days (Apr 30, 2027), making the timing of OrbiMed's position particularly relevant.
Short interest stands at 10.3% of float with 7.4 days to cover, indicating significant bearish positioning against the stock.
About Nkarta, Inc.
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Full company profile →Short Interest
10.3%
7.4 days to cover
OrbiMed Advisors NKTX Position History
Frequently Asked Questions
Does OrbiMed Advisors own NKTX?
No. OrbiMed Advisors exited their position in Nkarta, Inc. (NKTX) in Q2 2025. They previously held the stock for 6 quarters.
How many hedge funds own NKTX?
10 specialist biotech hedge funds currently hold NKTX, including RA Capital Management, Boxer Capital, Deerfield Management and 7 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did OrbiMed Advisors first buy NKTX?
OrbiMed Advisors's position in NKTX was first reported in Q1 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is OrbiMed Advisors's NKTX position increasing or decreasing?
OrbiMed Advisors completely exited their NKTX position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
NKTXCompany Page →
All fund holders, insider trades, catalysts, and cash runway
OrbiMed AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →